Last Updated: August 3, 2026

paroxetine mesylate - Profile


✉ Email this page to a colleague

« Back to Dashboard


What are the generic sources for paroxetine mesylate and what is the scope of patent protection?

Paroxetine mesylate is the generic ingredient in three branded drugs marketed by Legacy Pharma, Actavis Labs Fl Inc, Prinston Inc, and Sebela Ireland Ltd, and is included in four NDAs. There are three patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Paroxetine mesylate has forty-four patent family members in twenty-six countries.

Summary for paroxetine mesylate
International Patents:44
US Patents:3
Tradenames:3
Applicants:4
NDAs:4
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for paroxetine mesylate
Paragraph IV (Patent) Challenges for PAROXETINE MESYLATE
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
BRISDELLE Capsules paroxetine mesylate 7.5 mg 204516 1 2014-04-07

US Patents and Regulatory Information for paroxetine mesylate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Legacy Pharma BRISDELLE paroxetine mesylate CAPSULE;ORAL 204516-001 Jun 28, 2013 AB RX Yes Yes 8,946,251 ⤷  Start Trial Y Y ⤷  Start Trial
Legacy Pharma BRISDELLE paroxetine mesylate CAPSULE;ORAL 204516-001 Jun 28, 2013 AB RX Yes Yes 9,393,237 ⤷  Start Trial ⤷  Start Trial
Legacy Pharma BRISDELLE paroxetine mesylate CAPSULE;ORAL 204516-001 Jun 28, 2013 AB RX Yes Yes 8,658,663 ⤷  Start Trial Y Y ⤷  Start Trial
Actavis Labs Fl Inc PAROXETINE MESYLATE paroxetine mesylate CAPSULE;ORAL 207139-001 Jun 20, 2017 AB RX No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Prinston Inc PAROXETINE MESYLATE paroxetine mesylate CAPSULE;ORAL 207188-001 Aug 18, 2017 AB RX No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for paroxetine mesylate

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Sebela Ireland Ltd PEXEVA paroxetine mesylate TABLET;ORAL 021299-003 Jul 3, 2003 6,703,408 ⤷  Start Trial
Sebela Ireland Ltd PEXEVA paroxetine mesylate TABLET;ORAL 021299-002 Jul 3, 2003 7,598,271 ⤷  Start Trial
Legacy Pharma BRISDELLE paroxetine mesylate CAPSULE;ORAL 204516-001 Jun 28, 2013 5,874,447 ⤷  Start Trial
Sebela Ireland Ltd PEXEVA paroxetine mesylate TABLET;ORAL 021299-004 Jul 3, 2003 5,874,447 ⤷  Start Trial
Sebela Ireland Ltd PEXEVA paroxetine mesylate TABLET;ORAL 021299-003 Jul 3, 2003 5,874,447 ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for paroxetine mesylate

Country Patent Number Title Estimated Expiration
Australia 2007282065 Method of treating thermoregulatory disfunction with paroxetine ⤷  Start Trial
Brazil PI0715087 MÉTODO DE TRATAMENTO DE DISFUNÇÃO TERMOREGULATÓRIA COM PAROXETINA ⤷  Start Trial
Canada 2659577 METHODE POUR TRAITER UN DYSFONCTIONNEMENT DE THERMOREGULATION AVEC DE LA PAROXETINE (METHOD OF TREATING THERMOREGULATORY DISFUNCTION WITH PAROXETINE) ⤷  Start Trial
China 101505759 Method of treating thermoregulatory disfunction with paroxetine ⤷  Start Trial
Cyprus 1120867 ⤷  Start Trial
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.